Merck & Co., headquartered in Rahway, New Jersey, employs 72,000 people and provides health solutions through pharmaceuticals, vaccines, and animal health products. Its lead candidate is MK-6070, targeting DLL3.
MRK has been in the news recently: Merck & Co., Inc. reported positive topline results from two Phase 3 trials of enlicitide decanoate, an oral PCSK9 inhibitor for treating hyperlipidemia. The company's FDA-approved vaccine, Enflonsia, significantly reduces RSV-related hospitalizations in infants by over 84% compared to a placebo.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
